HomeCompareRGTPQ vs GBDC

RGTPQ vs GBDC: Dividend Comparison 2026

RGTPQ yields 1250.00% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RGTPQ wins by $135327056.81M in total portfolio value
10 years
RGTPQ
RGTPQ
● Live price
1250.00%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$135327077.59M
Annual income
$116,926,161,071,848.38
Full RGTPQ calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — RGTPQ vs GBDC

📍 RGTPQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGTPQGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGTPQ + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGTPQ pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGTPQ
Annual income on $10K today (after 15% tax)
$106,250.00/yr
After 10yr DRIP, annual income (after tax)
$99,387,236,911,071.11/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, RGTPQ beats the other by $99,387,222,980,197.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGTPQ + GBDC for your $10,000?

RGTPQ: 50%GBDC: 50%
100% GBDC50/50100% RGTPQ
Portfolio after 10yr
$67663549.18M
Annual income
$58,463,088,730,555.89/yr
Blended yield
86.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

RGTPQ
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGTPQ buys
0
GBDC buys
0
No recent congressional trades found for RGTPQ or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGTPQGBDC
Forward yield1250.00%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$135327077.59M$20.78M
Annual income after 10y$116,926,161,071,848.38$16,389,263.41
Total dividends collected$133960810.96M$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: RGTPQ vs GBDC ($10,000, DRIP)

YearRGTPQ PortfolioRGTPQ Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$135,700$125,000.00$12,490$1,790.28+$123.2KRGTPQ
2$1,730,479$1,585,280.37$16,522$3,157.73+$1.71MRGTPQ
3$20,744,959$18,893,346.29$23,578$5,898.68+$20.72MRGTPQ
4$233,872,934$211,675,827.14$37,115$11,886.75+$233.84MRGTPQ
5$2,480,500,804$2,230,256,765.05$66,136$26,423.57+$2480.43MRGTPQ
6$24,761,170,753$22,107,034,892.35$137,257$66,491.44+$24761.03MRGTPQ
7$232,737,122,500$206,242,669,794.36$341,734$194,868.54+$232736.78MRGTPQ
8$2,060,741,008,119$1,811,712,287,044.72$1,050,788$685,133.02+$2060739.96MRGTPQ
9$17,197,118,239,637$14,992,125,360,949.39$4,099,314$2,974,971.01+$17197114.14MRGTPQ
10$135,327,077,588,260$116,926,161,071,848.38$20,775,530$16,389,263.41+$135327056.81MRGTPQ

RGTPQ vs GBDC: Complete Analysis 2026

RGTPQStock

RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. The company was formerly known as PolarityTE, Inc. and changed its name to RegenETP, Inc. in August 2023. RegenETP, Inc. is headquartered in Salt Lake City, Utah.

Full RGTPQ Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this RGTPQ vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGTPQ vs SCHDRGTPQ vs JEPIRGTPQ vs ORGTPQ vs KORGTPQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.